Evidence map›Paper›PMID 35877026›Full record

ArticleProgress in biomaterials2022

Slow release curcumin-containing soy protein nanoparticles as anticancer agents for osteosarcoma: synthesis and characterization.

Hadi Zare-Zardini, Hossein Soltaninejad, Adel Ghorani-Azam, Reza Nafisi-Moghadam, Navid Haddadzadegan, Mojtaba Ansari, Seyed Houssein Saeed-Banadaki, Mohammad Reza Sobhan, Sima Mozafari, Mahlagha Zahedi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Progress in biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hadi Zare-ZardiniDepartment of Biomedical Engineering, Meybod University, Meybod, Iran. hadizarezardini@gmail.com.ORCID http://orcid.org/0000-0002-1501-2560
Hossein SoltaninejadFaculty of Interdisciplinary Science and Technology, Tarbiat Modares University, Tehran, Iran.
Adel Ghorani-AzamDepartment of Forensic Medicine and Toxicology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Reza Nafisi-MoghadamDepartment of Radiology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Navid HaddadzadeganDepartment of Anesthesiology and Critical Care, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Mojtaba AnsariHematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Seyed Houssein Saeed-BanadakiDepartment of Orthopedia, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Mohammad Reza SobhanDepartment of Orthopedia, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Sima MozafariHematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Mahlagha ZahediDepartment of Pathology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin-containing soy protein nanoparticles (curcumin-SPNs) were synthesized by desolvation (coacervation) method and characterized by SEM, DLS, FTIR, and XRD. For anticancer evaluation, osteogenic sarcoma (SAOS2) cell lines were incubated with different concentrations of nanostructures. The dialysis method was used for assessment of drug release. Intracellular reactive oxygen species (ROS) were evaluated in IC50 dose after 24 h of exposure to free curcumin and curcumin-SPNs. Characterization data showed that the size of drug-free SPNs and curcumin-SPNs were 278.2 and 294.7 nm, respectively. The zeta potential of drug-free SPNs and curcumin-SPNs were - 37.1 and - 36.51 mv, respectively. There was no significant difference between the control and drug-free SPNs groups in terms of cell viability (p > 0.05). The viability of cells in different concentrations of the designed curcumin-SPNs in Saos2 cell line was significantly higher than free drug (p < 0.05). The release of curcumin showed that more than 50% of the drug was released in the first 2 h of incubation. After this time, the slow release of drug was continued to 62-83% of drug. IC50 values of free curcumin and curcumin-SPNs (1/10) were 156.8 and 65.9 µg/mL, respectively (a free curcumin IC50 was 2.4 times more than curcumin-SPNs). Slow-release of the curcumin causes the cell to be exposed to the anticancer drug for a longer period of time. The intracellular ROS levels significantly increased in an IC50 dose after 24 h of exposure to both free curcumin and curcumin-SPNs compared with controls (p < 0.05).

Indexed as

CurcuminNanoparticleSaos2 cell linesSoy protein

Identifiers

PMID35877026
PMCPMC9374868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.